1. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient‐reported outcomes: a prospective study. (29th May 2018) Authors: Ghazanfar, M.N.; Holm, J.G.; Thomsen, S.F. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 10(2018) Page Start: 1761 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Epidermal biomarker levels differentiate lesional from non‐lesional skin and show variation across anatomical locations in patients with atopic dermatitis. (13th January 2021) Authors: Holm, J.G.; Clausen, M.L.; Agner, T.; Arildsen, N.S.; Jakasa, I.; Kezic, S.; Thomsen, S.F. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 5(2021) Page Start: e325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Quality of life and disease severity in patients with atopic dermatitis. (10th June 2016) Authors: Holm, J.G.; Agner, T.; Clausen, M.‐L.; Thomsen, S.F. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 10(2016:Oct.) Page Start: 1760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. (29th April 2019) Authors: Olesen, C.M.; Holm, J.G.; Nørreslet, L.B.; Serup, J.V.; Thomsen, S.F.; Agner, T. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 33:Number 8(2019) Page Start: 1562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗